Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid arthritis ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U.S. military veterans ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

In The Lancet Rheumatology, Bryant R England and colleagues 9 investigated the safety of TNF inhibitors and other biological or targeted synthetic DMARDs in patients with rheumatoid ...

However, there is little information as to whether ‘biologic-free remission’ is possible after sustained remission following intensive treatment with TNF inhibitors in RA. European studies such as ...

Over the last decade, TNF-α antagonists became the most powerful tools for controlling patient suffering from a number of rheumatic diseases. Infliximab, etanercept and adalimumab can induce ...

This suggests that weight management should be an integral part of treatment planning for RA patients, especially those on TNF inhibitors. Another study highlighted the differential responses to ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Methods 127 erosions were identified in metacarpophalangeal joints 2–4 of the right hands of 30 RA patients treated with tumour necrosis factor inhibitors (TNFi) and 21 sex, age and disease ...

BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on January 14.Invest with Confidence: ...

3 TNF inhibitor drug category: the global market value for TNF inhibitors was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor ...